PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8583213-5 1995 CSF QUIN levels were also elevated to a lesser degree in patients with hydrocephalus or tumors. Quinolinic Acid 4-8 colony stimulating factor 2 Homo sapiens 0-3 8583213-6 1995 CSF L-kynurenine levels increased in parallel to the accumulations in QUIN, which is consistent with increased activity of the first enzyme of the kynurenine pathway, indoleamine-2,3-dioxygenase. Quinolinic Acid 70-74 colony stimulating factor 2 Homo sapiens 0-3 15013955-13 2004 These studies show that CSF QUIN concentrations relate primarily to active CSF HIV infection and to a lesser extent to plasma QUIN. Quinolinic Acid 126-130 colony stimulating factor 2 Homo sapiens 24-27 19958238-8 2010 Metabolites downstream of IDO (kynurenine, quinolinic acid, kynurenic acid) were all induced in sepsis and declined in the GM-CSF group, but not in controls. Quinolinic Acid 43-58 colony stimulating factor 2 Homo sapiens 123-129 15013955-0 2004 CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Quinolinic Acid 4-19 colony stimulating factor 2 Homo sapiens 0-3 15013955-2 2004 Previous studies have shown correlations between increased CSF QUIN levels and the presence of the AIDS dementia complex (ADC), a neurodegenerative condition complicating late-stage human immunodeficiency virus type 1 (HIV) infection in some patients. Quinolinic Acid 63-67 colony stimulating factor 2 Homo sapiens 59-62 15013955-5 2004 The first was an exploratory cross-sectional analysis of a clinically heterogeneous sample of 62 HIV-infected subjects, examining correlations of CSF QUIN levels with CSF and plasma HIV RNA levels and other salient parameters of infection. Quinolinic Acid 150-154 colony stimulating factor 2 Homo sapiens 167-170 15013955-8 2004 The cross-sectional studies showed strong correlations of CSF QUIN with both CSF HIV RNA and blood QUIN levels, as well as with elevations in CSF white blood cells, CSF total protein and CSF:blood albumin ratio. Quinolinic Acid 62-66 colony stimulating factor 2 Homo sapiens 58-61 15013955-8 2004 The cross-sectional studies showed strong correlations of CSF QUIN with both CSF HIV RNA and blood QUIN levels, as well as with elevations in CSF white blood cells, CSF total protein and CSF:blood albumin ratio. Quinolinic Acid 62-66 colony stimulating factor 2 Homo sapiens 77-80 15013955-8 2004 The cross-sectional studies showed strong correlations of CSF QUIN with both CSF HIV RNA and blood QUIN levels, as well as with elevations in CSF white blood cells, CSF total protein and CSF:blood albumin ratio. Quinolinic Acid 62-66 colony stimulating factor 2 Homo sapiens 77-80 15013955-8 2004 The cross-sectional studies showed strong correlations of CSF QUIN with both CSF HIV RNA and blood QUIN levels, as well as with elevations in CSF white blood cells, CSF total protein and CSF:blood albumin ratio. Quinolinic Acid 62-66 colony stimulating factor 2 Homo sapiens 77-80 15013955-8 2004 The cross-sectional studies showed strong correlations of CSF QUIN with both CSF HIV RNA and blood QUIN levels, as well as with elevations in CSF white blood cells, CSF total protein and CSF:blood albumin ratio. Quinolinic Acid 62-66 colony stimulating factor 2 Homo sapiens 77-80 15013955-8 2004 The cross-sectional studies showed strong correlations of CSF QUIN with both CSF HIV RNA and blood QUIN levels, as well as with elevations in CSF white blood cells, CSF total protein and CSF:blood albumin ratio. Quinolinic Acid 99-103 colony stimulating factor 2 Homo sapiens 58-61 15013955-10 2004 Antiviral treatment reduced the CSF QUIN levels in all the longitudinally followed, treated subjects. Quinolinic Acid 36-40 colony stimulating factor 2 Homo sapiens 32-35 15013955-11 2004 Kinetic modelling of CSF QUIN decay indicated that CSF QUIN levels were driven primarily by CSF HIV infection with a lesser contribution from blood QUIN levels. Quinolinic Acid 25-29 colony stimulating factor 2 Homo sapiens 51-54 15013955-11 2004 Kinetic modelling of CSF QUIN decay indicated that CSF QUIN levels were driven primarily by CSF HIV infection with a lesser contribution from blood QUIN levels. Quinolinic Acid 55-59 colony stimulating factor 2 Homo sapiens 21-24 15013955-11 2004 Kinetic modelling of CSF QUIN decay indicated that CSF QUIN levels were driven primarily by CSF HIV infection with a lesser contribution from blood QUIN levels. Quinolinic Acid 55-59 colony stimulating factor 2 Homo sapiens 51-54 15013955-13 2004 These studies show that CSF QUIN concentrations relate primarily to active CSF HIV infection and to a lesser extent to plasma QUIN. Quinolinic Acid 28-32 colony stimulating factor 2 Homo sapiens 24-27 15013955-15 2004 The time course of therapy-induced changes links CSF QUIN to local infection and supports the action of antiviral therapy in ameliorating immunopathological brain injury and ADC. Quinolinic Acid 53-57 colony stimulating factor 2 Homo sapiens 49-52 10217295-1 1999 Although the neurotoxic tryptophan-kynurenine pathway metabolite quinolinic acid originates in brain by both local de novo synthesis and entry from blood, its concentrations in brain parenchyma, extracellular fluid, and CSF are normally below blood values. Quinolinic Acid 65-80 colony stimulating factor 2 Homo sapiens 220-223 11335705-3 2001 In the present cross-sectional study of 94 HIV-1-infected patients, elevated CSF quinolinic acid concentrations correlated with worsening brain atrophy, quantified by MRI, in regions vulnerable to excitotoxic injury (the striatum and limbic cortex) but not in regions relatively resistant to excitotoxicity (the non-limbic cortex, thalamus and white matter). Quinolinic Acid 81-96 colony stimulating factor 2 Homo sapiens 77-80 11335705-4 2001 Increased CSF quinolinic acid concentrations also correlated with higher CSF HIV-1 RNA levels. Quinolinic Acid 14-29 colony stimulating factor 2 Homo sapiens 10-13 11335705-4 2001 Increased CSF quinolinic acid concentrations also correlated with higher CSF HIV-1 RNA levels. Quinolinic Acid 14-29 colony stimulating factor 2 Homo sapiens 73-76 9626184-0 1998 Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. Quinolinic Acid 0-15 colony stimulating factor 2 Homo sapiens 32-35 9626184-1 1998 We tested the hypothesis that quinolinic acid, a tryptophan-derived N-methyl-D-aspartate agonist produced by macrophages and microglia, would be increased in CSF after severe traumatic brain injury (TBI) in humans, and that this increase would be associated with outcome. Quinolinic Acid 30-45 colony stimulating factor 2 Homo sapiens 158-161 9626184-8 1998 Quinolinic acid concentration in CSF increased maximally to 463 +/- 128 nmol/L (mean +/- SEM) at 72 to 83 hours after TBI. Quinolinic Acid 0-15 colony stimulating factor 2 Homo sapiens 33-36 9626184-9 1998 Normal values for quinolinic acid concentration in CSF are less than 50 nmol/L. Quinolinic Acid 18-33 colony stimulating factor 2 Homo sapiens 51-54 9626184-13 1998 These data reveal a large increase in quinolinic acid concentration in CSF after TBI in humans and raise the possibility that this macrophage-derived excitotoxin may contribute to secondary damage. Quinolinic Acid 38-53 colony stimulating factor 2 Homo sapiens 71-74 8972425-8 1996 We found that significant increases in the density of perivascular macrophages/microglia coincided with viral neuroinvasion and marked elevations in CSF quinolinic acid. Quinolinic Acid 153-168 colony stimulating factor 2 Homo sapiens 149-152